

PREFACE

These proceedings are based on presentations at a special *Toremifene Satellite Symposium* held at the *UICC World Cancer Congress* in Budapest 1986. The aim of these proceedings is to give an overview of the basic properties, preclinical profile and early clinical experience with the new triphenylethylene compound toremifene.

The long delay between the symposium and this publication is partly due to some of the authors being reluctant to get their manuscripts in on time, but more importantly as a result of the updating of some key pharmacokinetic, metabolic and clinical studies. At long last we are happy to publish a comprehensive overview of toremifene in a high quality international journal. Although many clinical reports are very preliminary, we hope that this authoritative report will encourage readers to conduct their own research on this interesting drug both in the laboratory and in the clinic, so that in time toremifene will find its appropriate place in the clinical oncologist's armamentarium.

MICHAEL BAUM
LAURI KANGAS